CPSC final rule on packaging law
This article was originally published in The Tan Sheet
Executive Summary
Manufacturers and importers of iron-containing vitamin supplements and OTC products must immediately comply with a law requiring certification of child-resistant packaging, the Consumer Product Safety Commission says in a final 1rule issued Nov. 10. Under the Consumer Product Safety Improvements Act, any packaged product containing 250 mg or more of elemental iron starting Nov. 12 needs to certify compliance with the Poison Prevention Packaging Act. Though CPSIA was enacted in August, industry stakeholders say they were not aware it would apply to food, drugs and cosmetics until CPSC clarified it Oct. 2 (2"The Tan Sheet" Nov. 10, 2008, p. 10). The final rule says enforcement will focus "more on the substantive requirements underlying the certificate than on the certificate or the form of the certificate itself," until Congress addresses CPSC's "resource limitations." The rule also confirms electronic certificates are appropriate. The Council for Responsible Nutrition and the Consumer Healthcare Products Association say CPSC did not respond to the trade groups' requests for more time and flexibility
You may also be interested in...
Package Certification Law Bears Down On Vitamins As Trade Groups Scramble
Vitamin supplement makers are adjusting begrudgingly to a certification requirement affecting packaging for products containing a certain amount of iron
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.